prikaz prve stranice dokumenta What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
  Download
PDF 544.64 KB
Scientific paper - Original scientific paper
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
Journal of Neural Transmission, 120 (2013), 1; 233-252. https://doi.org/10.1007/s00702-012-0877-9
Šalković-Petrišić, Melita; Knezović, Ana; Hoyer, Siegfried; Riederer, Peter

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Šalković Petrišić, M., Knezović, A., Hoyer, S. & Riederer, P. (2013). What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission, 120. (1), 233-252. doi: 10.1007/s00702-012-0877-9

Šalković Petrišić, Melita, et al. "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research." Journal of Neural Transmission, vol. 120, no. 1, 2013, pp. 233-252. https://doi.org/10.1007/s00702-012-0877-9

Šalković Petrišić, Melita, Ana Knezović, Siegfried Hoyer and Peter Riederer. "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research." Journal of Neural Transmission 120, no. 1 (2013): 233-252. https://doi.org/10.1007/s00702-012-0877-9

Šalković Petrišić, M., et al. (2013) 'What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research', Journal of Neural Transmission, 120(1), pp. 233-252. doi: 10.1007/s00702-012-0877-9

Šalković Petrišić M, Knezović A, Hoyer S, Riederer P. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. Journal of Neural Transmission [Internet]. 2013 January [cited 2024 April 29];120(1):233-252. doi: 10.1007/s00702-012-0877-9

M. Šalković Petrišić, A. Knezović, S. Hoyer and P. Riederer, "What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research", Journal of Neural Transmission, vol. 120, no. 1, pp. 233-252, January 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:642117. [Accessed: 29 April 2024]

Metadata
Title (english)What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research
AuthorMelita Šalković-Petrišić
AuthorAna Knezović
AuthorSiegfried Hoyer
AuthorPeter Riederer
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Experimental models that faithfully mimic the developmental pathology of sporadic Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic approaches in sAD treatment. Widely used transgenic mice AD models have provided valuable insights into the molecular mechanisms underlying the memory decline but, due to the particular β-amyloid-related gene manipulation, they resemble the familial but not the sporadic AD form, and are, therefore, inappropriate for this purpose. In line with the recent findings of sAD being recognised as an insulin resistant brains state (IRBS), a new, non-transgenic, animal model has been proposed as a representative model of sAD, developed by intracerebroventricular application of the betacytotoxic drug streptozotocin (STZ-icv). The STZ-icv-treated animals (mostly rats and mice) develop IRBS associated with memory impairment and progressive cholinergic deficits, glucose hypometabolism, oxidative stress and neurodegeneration that share many features in common with sAD in humans. The therapeutic strategies (acetylcholinesterase inhibitors, antioxidants and many other drugs) that have been tested until now on the STZ-icv animal model have been reviewed and the comparability of the drugs' efficacy in this non-transgenic sAD model and the results from clinical trials on sAD patients, evaluated.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleJournal of Neural Transmission
Numberingvol. 120, no. 1, pp. 233-252
p-ISSN0300-9564
DOIhttps://doi.org/10.1007/s00702-012-0877-9
URN:NBNurn:nbn:hr:105:642117
Publication2013-01
Document URLhttps://doi.org/10.1007/s00702-012-0877-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 19:35:34